T0	Participants 34 102	patients receiving androgen deprivation therapy for prostate cancer.
T1	Participants 185 209	advanced prostate cancer
T2	Participants 356 411	patients with prostate cancer during androgen ablation.
T3	Participants 494 519	advanced prostate cancer.
T4	Participants 753 848	Forty-eight osteoporotic patients with prostate cancer, treated with 3-month depot triptorelina
T5	Participants 929 937	(n = 24)
T6	Participants 1072 1080	(n = 24)
T7	Participants 2227 2265	men receiving ADT for prostate cancer.